Detemir dan Glargine: Profil Keamanan, Efikasi dan Farmakoekonomi Insulin Long-acting
DOI:
https://doi.org/10.31004/jptam.v5i3.3078Keywords:
Diabetes Melitus, Kadar Gula Darah, Detemir, GlargineAbstract
Diabetes melitus merupakan sebuah penyakit gangguan metabolik yang ditandai dengan adanya peningkatan kadar gula darah karena tubuh tidak dapat memproduksi insulin dengan efektif, sehingga diperlukan insulin buatan untuk mengontrol kadar gula darah. Detemir dan glargine merupakan terapi insulin yang dapat digunakan dengan durasi kerja lama dengan efek yang lebih konsisten dan penurunan resiko hipoglikemia. Penelitian ini dilakukan untuk mengetahui perbandingan antara detemir dan glargine berdasarkan profil keamanan, efikasi dan farmakoekonomi. Penelitian ini menggunakan metode review melalui database jurnal dengan kasus terkait studi analisis yang membandingkan antara detemir dan glargine berdasarkan profil keamanan, efikasi, dan farmakoekonomi. Penelitian dalam berbagai jurnal menyatakan bahwa tidak ada perbedaan secara efikasi antara penggunaan insulin detemir dan glargine dalam menurunkan kadar gula darah pasien. Pada kejadian hipoglikemia, kedua insulin tersebut tidak menunjukkan perbedaan. Namun, dari segi biaya menunjukkan adannya perbedaan yaitu insulin glargine lebih rendah dibandingkan insulin detemir. Berdasarkan hasil analisis yang review jurnal menyatakan bahwa detemir dan glargine merupakan terapi pengobatan pada pasien DM dengan kategori long acting insulin yang tidak menunjukkan perbedaan signifikan pada penurunan kadar gula darah dan tingkat kejadi hipoglikemi. Namun, terdapat perbedaan harga berupa insulin glargine lebih rendah dibandingkan insulin detemir.
References
Ahmad, M. et al. (2015) ‘Evaluation of Glycemia Control Achieved by Glargine and Lispro Versus Detemir and Aspart Insulin Regimes in Type 2 Diabetics Undergoing Surgery’, The Open Cardiovascular Medicine Journal, 9(1), pp. 58–61. doi: 10.2174/1874192401509010058.
Bracaglia (2017) ‘?????? HHS Public Access’, Physiology & behavior, 176(3), pp. 139–148. doi: 10.4158/EP171804.OR.Comparison.
Capson, J., Cade, K. and Avanesyan, A. (2019) ‘Detemir vs glargine: Comparison of inpatient glycemic control’, Journal of the American Osteopathic Association, 119(2), pp. 89–95. doi: 10.7556/jaoa.2019.014.
Crisher, M. A., Giuliano, C. A. and Hartner, C. L. (2019) ‘Insulin detemir versus insulin glargine in the hospital: Do hypoglycemia rates differ?’, Clinical Diabetes, 37(2), pp. 167–171. doi: 10.2337/cd18-0065.
Davis, S. et al. (2017) ‘Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol’, Pharmacy, 5(4), p. 22. doi: 10.3390/pharmacy5020022.
Rozea (2019) ‘Insulin Detemir (Levemir) information sheet’. Available at: http://www.diabetesuffolk.com/Insulin/Insulin detemir.htm.
WHO (2017) ‘General items Treatment details , public health relevance and evidence appraisal and synthesis’, pp. 1–16.
Elisha, B. et al. (2015) ‘Body Composition and Epicardial Fat in Type 2 Diabetes Patients Following Insulin Detemir Versus Insulin Glargine Initiation’, Hormone and Metabolic Research, 48(1), pp. 42–47. doi: 10.1055/s-0035-1554688.
George, J., Giuliano, C. A. and Hartner, C. L. (2021) ‘Glycemic Variability With Insulin Glargine Versus Detemir in Hospitalized Patients With Diabetes’, Journal of Pharmacy Practice. doi: 10.1177/08971900211017867.
Gripp, K. W., Ennis, S. and Napoli, J. (2013) ‘Exome Analysis in Clinical Practice: Expanding the Phenotype of Bartsocas-Papas Syndrome’, American Journal of Medical Genetics, Part A, pp. 1058–1063. doi: 10.1002/ajmg.a.35913.
Havelund, S. et al. (2004) ‘The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin’, Pharmaceutical Research, 21(8), pp. 1498–1504. doi: 10.1023/B:PHAM.0000036926.54824.37.
Hollander, P. et al. (2008) ‘A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes’, Clinical Therapeutics, 30(11), pp. 1976–1987. doi: 10.1016/j.clinthera.2008.11.001.
Kurtzhals, P. (2004) ‘Engineering predictability and protraction in a basal insulin analogue: The pharmacology of insulin detemir’, International Journal of Obesity, 28, pp. S23– S28. doi: 10.1038/sj.ijo.0802746.
Luzio, S. D. et al. (2013) ‘A comparison of the pharmacodynamic profiles of insulin detemir and insulin glargine: A single dose clamp study in people with type 2 diabetes’, Diabetes and Metabolism, 39(6), pp. 537–542. doi: 10.1016/j.diabet.2013.09.002.
Permsuwan, U. et al. (2017) ‘Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer’s perspective’, Journal of Medical Economics, 20(9), pp. 991–999. doi: 10.1080/13696998.2017.1347792.
Poon, K. and King, A. B. (2010) ‘Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs’, Drug, Healthcare and Patient Safety, 2(1), pp. 213–223. doi: 10.2147/DHPS.S7301.
Porcellati, F. et al. (2008) ‘Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: A double-blind, randomized, crossover study’, Diabetes Care, 31(3). doi: 10.2337/dc07-2234.
Razzaghy-azar, M., Momeni, H. and Nourbakhsh, M. (2021) ‘Comparison of Insulin Glargine and Detemir Effects on Hormones of Appetite and Metabolic Control in Patients with Type 1 Diabetes?: A Randomized Clinical Trial’, 20(July), pp. 647–653. doi: 10.22037/ijpr.2021.114841.15059.
Rosenstock, J. et al. (2008) ‘A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes’, Diabetologia, 51(3), pp. 408–416. doi: 10.1007/s00125-007-0911-x.
Santi Deliani Rahmawati, H. S. (2020) ‘No ???????????????????? ? ?????????????????Title’, 3(2017), pp. 54–67. Available at: http://repositorio.unan.edu.ni/2986/1/5624.pdf.
Shafie, A. A. and Ng, C. H. (2020) ‘Cost-effectiveness of insulin glargine and insulin detemir in the basal regimen for naïve insulin patients with type 2 diabetes mellitus (T2dm) in malaysia’, ClinicoEconomics and Outcomes Research, 12, pp. 333–343. doi: 10.2147/CEOR.S244884.
Soelistijo Soebagijo Adi, et all (2019) ‘Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia’, Perkeni, p. 133.
Soiza, R. L., Donaldson, A. I. C. and Myint, P. K. (2018) ‘Vaccine against arteriosclerosis: an update’, Therapeutic Advances in Vaccines, 9(6), pp. 259–261. doi: 10.1177/https.
Swinnen, S. G. et al. (2013) ‘Insulin detemir versus insulin glargine for type 2diabetes mellitus’, Diabetes Technology and Therapeutics, 15(SUPPL.1). doi: 10.1089/dia.2013.1505.
Tokarz, V. L., MacDonald, P. E. and Klip, A. (2018) ‘The cell biology of systemic insulin function’, Journal of Cell Biology, 217(7), pp. 2273–2289. doi: 10.1083/jcb.201802095.
Wallace, J. P., Wallace, J. L. and McFarland, M. S. (2014) ‘Comparing Dosing of Basal Insulin Analogues Detemir and Glargine: Is It Really Unit-Per-Unit and Dose-Per- Dose?’, Annals of Pharmacotherapy, 48(3), pp. 361–368. doi: 10.1177/1060028013518420.
Yamada, S. et al. (2011) ‘Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring’, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, p. 283. doi: 10.2147/dmso.s21513.
Zhang, T. et al. (2016) ‘Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial’, Advances in Therapy, 33(2), pp. 178–185. doi: 10.1007/s12325-016-0288-7.
Downloads
Published
How to Cite
Issue
Section
Citation Check
License
Copyright (c) 2021 Luthfi Hidayat, Nuraini Maulidina Sari, Noviary Nur Mutmainah
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
